Cargando…

PB2143: CLINICAL CHARACTERISTICS AND PROGNOSTIC FEATURES OF 63 HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER REAL-WORLD STUDY IN CHINA

Detalles Bibliográficos
Autores principales:	Wang, C., Liu, J., Liang, X., Liu, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429674/ http://dx.doi.org/10.1097/01.HS9.0000851404.48738.35

Ejemplares similares

PB2143: PROGNOSTIC SIGNIFICANCE AND CLINICAL APPLICABILITY OF THE COMORBIDITY INDICES IN PATIENTS WITH MULTIPLE MYELOMA: IMWG AND SARC-F SCORE
por: Vukosavljevic, Nikola, et al.
Publicado: (2023)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE
por: Zhang, Y., et al.
Publicado: (2022)

PB2360: HIV-ASSOCIATED BURKITT LYMPHOMA IN THE COMBINATION ANTIRETROVIRAL THERAPY ERA: REAL-WORLD OUTCOMES AND PROGNOSTICATION
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, Elena, et al.
Publicado: (2023)

PB2354: DIFFUSE LARGE B CELL LYMPHOMA IN 65: DIAGNOSTIC, PROGNOSTIC, PROGRESSIVE AND THERAPEUTIC ASPECTS
por: Mlayah, Zaineb, et al.
Publicado: (2023)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2306: REAL-WORLD FIRST-LINE TREATMENT AND OUTCOMES AMONG PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE
por: Yan, Jiali, et al.
Publicado: (2023)

PB2678: THE PROGNOSTIC SIGNIFICANCE OF CONTROLLING NUTRITIONAL STATUS AND SARCOPENIA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Go, Se‑il, et al.
Publicado: (2023)

PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Lakhwani, Sunil Lakhwani, et al.
Publicado: (2023)

PB2108: PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
por: Liang, X., et al.
Publicado: (2022)

PB2348: OUTCOME OF VERY ELDERLY DIFFUSE LARGE B CELL LYMPHOMA, SINGLE CENTER EXPERIENCE, RETROSPECTIVE ANALYSIS
por: Kong, Jee Hyun, et al.
Publicado: (2023)

PB2274: REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY
por: Ko, Bor-Sheng, et al.
Publicado: (2023)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2361: DIFFUSE LARGE B-CELL LYMPHOMA IN THE ELDERLY: RETROSPECTIVE ANALYSIS FROM A SINGLE CANCER CENTER IN ALGIERS
por: Faiza, Talbi, et al.
Publicado: (2023)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
por: Zhang, Xudong, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

PB2141: CLINICOPATHOLOGICAL FEATURES AND OUTCOME OF CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA AND THE SIGNIFICANCE OF CD5 EXPRESSION STRENGTH: 10-YEAR SINGLE CENTER EXPERIENCE
por: Vukovic, V., et al.
Publicado: (2022)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

PB2302: A TRNA-DERIVED SMALL RNAS EXPRESSION SIGNATURE AS A PREDICTIVE AND PROGNOSTIC BIOMARKER IN DIFFUSE LARGE B CELL LYMPHOMA
por: Rao, Jun, et al.
Publicado: (2023)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

PB2327: IS THERE ANY VALUE OF GERIATRIC INDICES IN DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY?
por: Dragčević, Dora, et al.
Publicado: (2023)

PB2098: ‘REAL-WORLD’ TREATMENT PATTERNS AND PATHWAYS OF SECOND LINE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN UK, CANADA, FRANCE, GERMANY, ITALY AND SPAIN USING A PROSPECTIVE SURVEY OF PHYSICIANS
por: Bailey, A., et al.
Publicado: (2022)

PB2574: HEMOPHAGOCYTIC SYNDROME IN ADULTS - REAL-WORLD DATA ON MORTALITY FROM A TERTIARY REFERENCE CENTER
por: Wojtovicova, Tatiana, et al.
Publicado: (2023)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION
por: Yan-Li, L., et al.
Publicado: (2022)

PB2374: DIFFERENCES IN MUTATIONAL SIGNATURE OF DIFFUSE LARGE B-CELL LYMPHOMAS ACCORDING TO THE PRIMARY ORGAN
por: Koh, Hyun Hee, et al.
Publicado: (2023)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP
por: Filonenko, K., et al.
Publicado: (2022)

PB2395: ASSOCIATIONS BETWEEN GLYCOLYSIS PATTERNS AND IMMUNE CELL INFILTRATION IN THE TUMOR MICROENVIRONMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
por: Liu, Zhenyu, et al.
Publicado: (2023)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4un5gqaarqqr15ld7pjkqcatln